Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies
暂无分享,去创建一个
C. Briani | D. Cecchin | L. De Michieli | A. Cipriani | K. Pilichou | A. Salvalaggio | M. Cason | P. Artioli | G. Sinigiani | S. Righetto
[1] P. Elliott,et al. Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis , 2021, EJNMMI Research.
[2] Sanjiv J. Shah,et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. , 2021, Circulation. Cardiovascular imaging.
[3] M. Anselmino,et al. The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy , 2021, Journal of Nuclear Cardiology.
[4] T. Heliö,et al. Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy , 2020, Journal of Nuclear Cardiology.
[5] J. Butler,et al. Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? , 2020, European journal of heart failure.
[6] Sanjiv J. Shah,et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization , 2019, Journal of Nuclear Cardiology.
[7] V. Murthy,et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. , 2019, Journal of cardiac failure.
[8] M. Slama,et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease , 2019, Nature Reviews Neurology.
[9] M. Emdin,et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis , 2019, Journal of Nuclear Cardiology.
[10] M. Kürtüncü,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.
[11] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[12] M. Sweetser,et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[13] K. Shah,et al. Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.
[14] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[15] M. Skinner,et al. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study , 2016, Circulation.
[16] F. Salvi,et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. , 2014, JACC. Cardiovascular imaging.
[17] F. Salvi,et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.
[18] Keyur B Shah,et al. Amyloidosis and the heart: a comprehensive review. , 2006, Archives of internal medicine.
[19] F. Salvi,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.
[20] V. R. McCready,et al. Clinical significance of technetium-99m methylene diphosphonate myocardial uptake: association with carcinoma of the prostate , 1995, European Journal of Nuclear Medicine.
[21] H. Hodkinson,et al. The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. , 1977, The Quarterly journal of medicine.